Abstract
Oral vemurafenib (Zelboraf(®)) is a first-in-class, small molecule BRAF(V600E) inhibitor indicated for the treatment of unresectable or metastatic melanoma in BRAF(V600) mutation-positive patients (EU) or BRAF(V600E) mutation-positive patients (USA). Compared with intravenous dacarbazine, vemurafenib significantly improved overall survival and progression-free survival in patients with unresectable, previously untreated, BRAF(V600E) mutation-positive, stage IIIC or IV melanoma. Oral vemurafenib was generally well tolerated, with cutaneous adverse events among the most commonly occurring adverse events.
MeSH terms
-
Administration, Oral
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Disease-Free Survival
-
Humans
-
Indoles / adverse effects
-
Indoles / therapeutic use*
-
Melanoma / drug therapy*
-
Melanoma / pathology
-
Mutation
-
Neoplasm Metastasis
-
Neoplasm Staging
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Proto-Oncogene Proteins B-raf / genetics
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / pathology
-
Sulfonamides / adverse effects
-
Sulfonamides / therapeutic use*
-
Survival Rate
-
Vemurafenib
Substances
-
Antineoplastic Agents
-
Indoles
-
Sulfonamides
-
Vemurafenib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf